Ironwood Pharmaceuticals is trading 5.96% higher at $4.27 after management raised 2026 guidance. - November 5 third-quarter results showed revenue of $133.0 million and diluted GAAP EPS of $0.36. - Management raised 2026 total revenue guidance to $485–$510 million and LINZESS U.S. sales guidance to $1.20–$1.25 billion, citing continued product strength.